THE IMPACT OF METABOLIC SYNDROME ON THE DIAGNOSIS OF SECOND PRIMARY TUMORS IN WOMEN TREATED FOR BREAST CANCER: A RETROSPECTIVE COHORT ANALYSIS ambrogio.londero@gmail.com

3103-04

THE IMPACT OF METABOLIC SYNDROME ON THE DIAGNOSIS OF SECOND PRIMARY TUMORS IN WOMEN TREATED FOR BREAST CANCER: A RETROSPECTIVE COHORT ANALYSIS

7

Italy

Oral or Poster

Metabolic syndrome (MetS) is characterized by central adiposity, hypertension, hyperglycemia, dyslipidemia, and insulin resistance. It has been associated with both the incidence of breast cancer (BC) and long-term oncologic outcomes. We hypothesize that MetS elevates the risk of multiple primary tumors.

This retrospective cohort study involved 7,696 women treated for BC from 2002 to 2024. MetS was identified through documented components (body mass index as a proxy for waist circumference, hypertension, diabetes or impaired glucose tolerance) and categorized based on the number of elements present (0, 1, ≥2).

850 (11.1%) were found with at least one second primary tumor, either breast or non-breast. In the BC-only group, 48.11% exhibited at least one component of MetS, which was significantly lower than the rates observed in those with a second primary (53.06%) and those with >2 primaries (59.29%) (p<0.05). In multivariate analysis, the presence of one MetS component was linked to a 62% increase in the odds of a second tumor (OR 1.62; 95% CI 1.42-1.85; p < 0.05), while the presence of two or more components resulted in a 44% higher odds (OR 1.44; 95% CI 1.12-1.87; p<0.05).

MetS is an independent risk factor for the development of multiple primary tumors. The findings underscore the significance of enhancing metabolic health in BC survivors to potentially mitigate the risk of further primary cancers during follow-up.